Sungmin Park1, Jeong Eon Lee2, Jai Min Ryu3, Issac Kim3, Soo Youn Bae4, Se Kyung Lee3, Jonghan Yu3, Seok Won Kim3, Seok Jin Nam3. 1. Department of Surgery, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea. 2. Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. jeongeon.lee@samsung.com. 3. Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. 4. Division of Breast and Endocrine Surgery, Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: The first aim of our study was to evaluate surgical decision-making by BRCA mutation carriers with breast cancer based on the timing of knowledge of their BRCA mutation status. The second aim was to evaluate breast cancer outcome following surgical treatment. METHODS: This was a retrospective study of 164 patients diagnosed with invasive breast cancer, tested for BRCA mutation, and treated with primary surgery between 2004 and 2015 at Samsung Medical Center in Seoul, Korea. We reviewed types of surgery and timing of the BRCA test result. We compared surgical decision- making of BRCA carriers with breast cancer based on the timing of knowledge of their BRCA mutation status. RESULTS: Only 15 (9.1%) patients knew their BRCA test results before their surgery, and 149 (90.9%) knew the results after surgery. In patients with unilateral cancer, there was a significant difference between groups whose BRCA mutation status known before surgery and groups whose BRCA status unknown before surgery regarding the choice of surgery (p = 0.017). No significant difference was observed across surgery types of risk of ipsilateral breast tumor recurrence (p = 0.765) and contralateral breast cancer (p = 0.69). CONCLUSION: Genetic diagnosis before surgery has an impact on surgical decision choosing unilateral mastectomy or bilateral mastectomy in BRCA mutation carriers with breast cancer. Knowledge about BRCA mutation status after initial surgery led to additional surgeries for patients with BCS. Thus, providing genetic counseling and genetic testing before surgical choice and developing treatment strategies for patients with a high risk of breast cancer are important.
BACKGROUND: The first aim of our study was to evaluate surgical decision-making by BRCA mutation carriers with breast cancer based on the timing of knowledge of their BRCA mutation status. The second aim was to evaluate breast cancer outcome following surgical treatment. METHODS: This was a retrospective study of 164 patients diagnosed with invasive breast cancer, tested for BRCA mutation, and treated with primary surgery between 2004 and 2015 at Samsung Medical Center in Seoul, Korea. We reviewed types of surgery and timing of the BRCA test result. We compared surgical decision- making of BRCA carriers with breast cancer based on the timing of knowledge of their BRCA mutation status. RESULTS: Only 15 (9.1%) patients knew their BRCA test results before their surgery, and 149 (90.9%) knew the results after surgery. In patients with unilateral cancer, there was a significant difference between groups whose BRCA mutation status known before surgery and groups whose BRCA status unknown before surgery regarding the choice of surgery (p = 0.017). No significant difference was observed across surgery types of risk of ipsilateral breast tumor recurrence (p = 0.765) and contralateral breast cancer (p = 0.69). CONCLUSION: Genetic diagnosis before surgery has an impact on surgical decision choosing unilateral mastectomy or bilateral mastectomy in BRCA mutation carriers with breast cancer. Knowledge about BRCA mutation status after initial surgery led to additional surgeries for patients with BCS. Thus, providing genetic counseling and genetic testing before surgical choice and developing treatment strategies for patients with a high risk of breast cancer are important.
Authors: Sang Ah Han; Sue K Park; Sei Hyun Ahn; Min Hyuk Lee; Dong-Young Noh; Lee Su Kim; Woo-Chul Noh; Yongsik Jung; Ku Sang Kim; Sung-Won Kim Journal: Clin Oncol (R Coll Radiol) Date: 2011-04-16 Impact factor: 4.126
Authors: D Gareth R Evans; Sarah L Ingham; Andrew Baildam; Gary L Ross; Fiona Lalloo; Iain Buchan; Anthony Howell Journal: Breast Cancer Res Treat Date: 2013-06-20 Impact factor: 4.872
Authors: D G R Evans; F Lalloo; P Hopwood; A Maurice; A Baildam; A Brain; L Barr; A Howell Journal: Eur J Surg Oncol Date: 2005-07-07 Impact factor: 4.424
Authors: Veronica F Quinn; Bettina Meiser; Judy Kirk; Kathy M Tucker; Kaaren J Watts; Belinda Rahman; Michelle Peate; Christobel Saunders; Elizabeth Geelhoed; Margaret Gleeson; Kristine Barlow-Stewart; Michael Field; Marion Harris; Yoland C Antill; Linda Cicciarelli; Karen Crowe; Michael T Bowen; Gillian Mitchell Journal: Genet Med Date: 2016-09-29 Impact factor: 8.822
Authors: D Gareth Evans; Julie Wisely; Tara Clancy; Fiona Lalloo; Mary Wilson; Richard Johnson; Jonathon Duncan; Lester Barr; Ashu Gandhi; Anthony Howell Journal: Breast Cancer Res Date: 2015-11-25 Impact factor: 6.466
Authors: Kristin E Rojas; Elizabeth Butler; Julie Gutierrez; Rebecca Kwait; Jessica Laprise; Jennifer Scalia Wilbur; Sarah Spinette; Christina A Raker; Katina Robison; Robert Legare; Jennifer Gass; Ashley Stuckey Journal: Gland Surg Date: 2019-06